ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

2023 Menopause Update

Yale School of Medicine

M. Minkin

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Insights from 2023 ASCO® Annual Meeting

H. Rugo, K. Jhaveri

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clini…

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo